Marker Therapeutics, Inc. (MRKR) Stock

Marker Therapeutics, Inc. is a pioneering clinical-stage immuno-oncology company focused on advancing T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumors across the United States. Established in 1999 and headquartered in Houston, Texas, Marker Therapeutics specializes in leveraging its proprietary MultiTAA-specific T cell technology. This innovative approach involves the production of non-engineered tumor-specific T cells capable of targeting multiple tumor-associated antigens, thereby enhancing their ability to eliminate tumor cells expressing these antigens.

The company's diverse pipeline includes autologous T cell therapies designed for lymphoma and various solid tumors, as well as allogeneic T cell therapies targeting acute myeloid leukemia and acute lymphoblastic leukemia. Marker Therapeutics is also advancing off-the-shelf products aimed at addressing critical unmet needs in oncology. Additionally, the company is developing TPIV100/110, peptide-based immunotherapeutic vaccines intended for the treatment of breast and ovarian cancers, and TPIV200, currently undergoing Phase 2 clinical trials for similar indications.

Driven by a commitment to innovation and patient-centric healthcare solutions, Marker Therapeutics continues to expand its capabilities in the rapidly evolving field of immuno-oncology. With a robust clinical development strategy and strategic focus on advancing transformative therapies, Marker Therapeutics remains dedicated to improving outcomes for patients battling cancer worldwide.